![](/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--e623d2450603cd9d4e6c86eae39da2c5b7f7bdd9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdERG9MY21WemFYcGxTU0lOTXpJd2VERTRNRjRHT2daRlZEb0pZM0p2Y0VraUVETXlNSGd4T0RBck1Dc3dCanNHVkRvTVozSmhkbWwwZVVraUMyTmxiblJsY2dZN0JsUTZESEYxWVd4cGRIbHBWVG9LYzNSeWFYQlVPZzVwYm5SbGNteGhZMlZKSWdsTWFXNWxCanNHVkRvTFpHVm1hVzVsU1NJZWFuQmxaenBtWVc1amVTMTFjSE5oYlhCc2FXNW5QVzltWmdZN0JsUT0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--daee5f4cd191d67586af9b48495fbde7d4763d64/lucas-vasques-453684-unsplash.jpg)
Search
Selected Filters
Filter Results
Displaying 191–200 of 274 research results
-
Mar 20, 2018
Best Disease Gene Therapy Advances Toward Clinical Trial
Using gene therapy, FFB-funded researchers at the University of Pennsylvania School of Veterinary Medicine (Penn Vet) and Perelman School of Medicine have reversed the disease process in a canine model of Best disease, an inherited form of macular degeneration that can lead to severe vision loss in humans
-
Mar 8, 2018
Choroideremia Gene Therapy Moves into Phase 3 Human Study
Nightstar Therapeutics, a retinal-disease, gene-therapy development company in the UK, is advancing its emerging gene therapy for choroideremia into a Phase 3 clinical trial known as STAR. The study will enroll approximately 140 patients at 18 clinical sites in the US, Europe, Canada, and South America.
-
Mar 7, 2018
Natural History Study Launches for LCA Caused by Specific Mutation in CEP290
The natural history study will be used to characterize the range of visual function in patients, to evaluate which visual tests may be the most useful for patients with this condition, and to determine the rate of change in visual function over a one-year period.
-
Feb 14, 2018
FFB-CRI Investing $7.5 Million in Emerging Therapy for USH2A
The Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) has entered into a partnership with ProQR to develop a retinal therapy for people with Usher syndrome type 2A (USH2A) caused by mutations in exon 13 of the USH2A gene.
-
Feb 7, 2018
AGTC Launches XLRP Gene Therapy Clinical Trial at Five Sites in U.S.
Taking place at five locations in the United States, the clinical trial will enroll approximately 15 males with X-linked retinitis pigmentosa caused by mutations in the gene RPGR and will primarily evaluate safety.
-
Jan 23, 2018
Ophthotech Launching Human Study of Emerging Therapy for Stargardt Disease
Ophthotech, a biopharmaceutical company developing therapies for eye diseases, has enrolled the first patient in its Phase 2b clinical trial of Zimura® for people with Stargardt disease caused by mutations in the gene ABCA4.
-
Jan 17, 2018
Clinical Trial to Launch for System Combining Optogenetics and Eyewear
The French biotech GenSight Biologics has received regulatory authorization in the UK to launch the PIONEER Phase 1 \ 2 clinical trial for its GS030 system — a light-sensing gene therapy (optogenetics) coupled with eyewear, which enhances visual stimulation.
-
Jan 9, 2018
Top Retinal Research Advances for 2017
An exciting year in fighting blindness.
-
Dec 21, 2017
jCyte Reports Results for Phase 1/2a Clinical Trial for Retinal-Cell Treatment
Some participants reported increased light sensitivity, improved color vision, better mobility, and improved reading ability.
-
Dec 20, 2017
History Is Made: FDA Approves Spark's Vision-Restoring Gene Therapy
Known as LUXTURNA™ (voretigene neparvovec), the gene therapy restored vision in a clinical trial for people between the ages of 4 and 44 with Leber congenital amaurosis (LCA) caused by mutations in the gene RPE65.